← Eichor
Study identifier: NCT07582042 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).

Condition: Geographic Atrophy From Age-related Macular Degeneration  ·  Sponsor: University of Utah

PhaseN/A
Planned participants50
Who can joinAll sexes, 65 Years to 90 Years
Healthy volunteersNo

About this study

The goal of this observational study is to evaluate changes in retinal sensitivity over time in patients with geographic atrophy due to age related macular degeneration who are receiving pegcetacoplan as part of routine clinical care. The study aims to determine whether lesion tailored fundus-controlled perimetry can reliably measure functional changes near areas of atrophy and whether this testing can be implemented in everyday clinic care over 24 months. Participants will undergo repeated vision testing, standard eye imaging, and visual function questionnaires while continuing their prescribed treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Jenny Mireles  ·  +1  ·  jenny.mireles@utah.edu

Ray Nelson  ·  +1  ·  ray.nelson@hsc.utah.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Utah, Department of Ophthalmology, John A. Moran Eye CenterSalt Lake City, Utah, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07582042